Concepedia

Leanne Lanieri

LL

Statistics

Publications

16

Citations

944

H-Index

14

Active since

2011

Affiliations

ImmunoGen (United States)(Current)

Fred Hutch Cancer Center

National Institutes of Health

Harvard Stem Cell Institute

University of Washington

Leanne Lanieri is an author at ImmunoGen (United States) specializing in antibody-drug conjugates, pharmacology, and antibody conjugates.

Publications per year

2011–2024

16

Publications

16

Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Xiuxia Sun, Jose F. Ponte, Nicholas C. Yoder et al. · Bioconjugate Chemistry · 2017 · 253 citations

Pharmacy, Oncology, Pharmacology +17

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

Jose F. Ponte, Olga Ab, Leanne Lanieri et al. · Neoplasia · 2016 · 112 citations · Full text

Medicine, Oncology, Pharmacology +16

Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV)

Aurelio Bonavia, Michael Franti, Erin P. Keaney et al. · Proceedings of the National Academy of Sciences · 2011 · 94 citations

Medicine, Infectious Diseases, Pharmacology +16

Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody–Maytansinoid Conjugates

Jose F. Ponte, Xiuxia Sun, Nicholas C. Yoder et al. · Bioconjugate Chemistry · 2016 · 79 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)

Michael L. Miller, Manami Shizuka, Alan Wilhelm et al. · Molecular Cancer Therapeutics · 2018 · 55 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +14

1–5 of 16